Gilead Sciences (GILD) has been a leader in the resurgent Biotech group. Gilead recovered from the steep drop in the Biotech group in March and April and has been outperforming the group and the overall market since mid-May. With GILD leading the Biotech stocks to new highs, all eyes will be on their earnings report due out this week. Gilead gave us a clue to … Continue reading Biotech Stock To Buy Now: Gilead Sciences (GILD)
Harvoni is the new tablet launched this month by Gilead Sciences, Inc (NASDAQ GILD) which Stewart acquired first because she take part in its clinical trials. Harvoni is a mixture of the novel drug ledipasvir and sofosbuvir, which for closely a year has been sold only under the brand name Sovaldi. Sovaldi’s launch shattered all earlier new drug launches. Since it came out in December … Continue reading Biotech News: A Look At The Most Active Biotech Stocks In The Market
Biotechnology investors often have to make bets based more on promise than profit. That’s because it takes years and hundreds of millions of dollars to advance new medicine through clinical trials to market, so investing in biotech stocks is more of a gamble than investing in other industries. Having said that, there are a number of biotech stocks that make money and that are expected … Continue reading Biotech Stock Analysis: Best Biotech Stocks in the Market Currently
Biotech stocks to buy aren’t exactly the most popular investments on Wall Street right now. The “risk on” environment of 2013 seems to have evaporated, with volatility heating up and many investors taking shelter in old stalwarts like consumer staples and even bond funds. Biotech stocks are often seen as risky and more speculative by investors, particularly those who prefer entrenched health care stocks like … Continue reading Biotech Stock News: The Best Biotech Stocks In The Market Right Now
Tax inversion deals are no longer looking so attractive given the notice issued by the U.S. Department of Treasury in September. In fact, AbbVie (ABBV) has dropped its plans to acquire Shire and will be paying a break-up fee. Meanwhile, Amgen (AMGN) is being urged to consider splitting into two companies which would create more value. AbbVie called off its plans to acquire Shire – … Continue reading Biotech Stock News: A Look At The Best Prospects For The Week
Pharmacyclics (PCYC) announced that it has teamed up with Roche (RHHBY) for evaluating the safety, tolerability and preliminary efficacy of its oncology treatment, Imbruvica, in combination with the latter’s Gazyva. The companies will assess the cocktail therapy in patients with non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in multiple clinical trials. As per the deal, the combination will initially be evaluated in … Continue reading Biotech Stocks Making Headlines: Pharmacyclics, Roche Ink Deal for Cancer Combo Therapy
